Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > 1y ago: The launch of the Anti-Cancer Therapy Research
View:
Post by ScienceFirst on Mar 28, 2022 8:48pm

1y ago: The launch of the Anti-Cancer Therapy Research

Theralase launches Anti-Cancer Therapy Research Centre

Toronto, Ontario – March 29, 2021

located within the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Unity Health Toronto, effective April 1, 2022, relocating its research team from University Health Network (“UHN”), Toronto.

The Li Ka Shing Knowledge Institute of St. Michael’s is home to leading researchers, educators and clinicians — dedicated professionals making new scientific discoveries, generating novel therapies, developing innovative training programs and helping translate knowledge into practice.

The ACT research centre is a fully equipped laboratory dedicated exclusively to Theralase® ACT research and development as it advances towards commercialization with its lead PDC, TLD-1433, as well as its systemic and targeted formulation – Rutherrin®. A Partnership with the Li Ka Shing Knowledge Institute of Unity Health provides access to additional expertise, advisory networks and opportunities to accelerate product development and commercialization.


__________________

This research center has been created for very strategic reasons, one year ago.  They wouldn't have created this just for fun, without knowing they can go commercial with PDT/PDC.  In the meantime, they had to let the Ph. 2b trial continue to proceed and allow data to be collected.  COVID-19 has slowed things a bit, but enrollment continues.

So this Anti-Cancer Therapy Research, within the institute of a billionnaire is there to offer continuity, bring this to mainstream and bedside and allow our full valuation.  There's no other reason. 

Not sure the April 1, 2022 was a typo or not but it doesn't matter much.  What matters is that they planned the next move and this next move is commercialization.

Not a big pharma has the luxury (over competitors) to ignore such a market dominance if our %CR and %DR are above anything else on the market as this would mean total dominance of the bladder market for years.  BCG, with poor efficacy results, many treatments and 50%+ recurrence rate, has been able to dominate for 40 years simply because of lack of R&D investments in the bladder indication.  So if we hit 50%+, don't think that, all of a sudden, some will start investing in NMIBC R&D.  So we<ll be there for a while (2054).

PDT/PDC gainst NMIBC destroys instantly, with no side effects, with 2 doses, and could be repeated, if needed!

The FDA will not ignore that, especially when it can help delay cystectomy for few months.  Or better than that; simply avoid it and save a bladder.

We've seen many treatments receiving Breakthrough designation just for few additional months of survival benefits.   TLT's technology has the ability to save bladders, avoid 6-7 hour life-threatening surgeries, restore quality of life (QOL), an important indicator that all specialists always look at.

Such stand-alone treatment is worth B$$$.  If we reconfirm our efficacy ratios, not only urologists will have jaw-dropping reactions but also all the oncology industry.  And we have other PDCs in our portfolios, on top of Rutherrin and TLD-1433.

Comment by BlueFranky on Mar 28, 2022 9:13pm
Thank you science for a great write up as usual I continue to have one question Why in the hell are we still sitting at this price?
Comment by robertshaw on Mar 28, 2022 9:36pm
all the thanks give to Blowjobjoe's bosses..
Comment by ScienceFirst on Mar 28, 2022 10:08pm
Bluefranky ... For the same reason you see some stocks skyrock out of nowhere. Market will give us appropriate valuation as we get closer to the goal line and will play catch if required on clear data.
Comment by BlueFranky on Mar 28, 2022 10:31pm
Science I've heard that so many times now you think it would become second nature instead of cognitive dissonance that said, I'd have thought that the data thus far, the trending that has been taking place .. along with all of the other pieces that are in the pipeline would have us sitting north of a buck already.. Yet I have faith that we'll be duly rewarded ;-)
Comment by Pandora on Mar 28, 2022 10:41pm
BlueFrancky you could always take a look at this video regarding bureaucracy: https://youtu.be/vZlZIXHT0yA Note - it's a repeat from earlier.
Comment by CancerSlayer on Mar 29, 2022 2:19am
Well said...re: your following comment: "TLT's technology has the ability to save bladders, avoid 6-7 hour life-threatening surgeries, restore quality of life (QOL), an important indicator that all specialists always look at." I agree...QOL is ultimately the most important measure of treatment success for both patients & docs.  With FDA approval, I would hope our esteemed ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250